Photo from Kimryn Rathmell/X
Mar 8, 2024, 19:07
Kimryn Rathmell: New drug type in the kidney cancer space and the value of rare disease research
Kimryn Rathmell, Director of
“I’m excited to see that the discovery of a drug to target HIF-2alpha, first developed for a rare disease (VHL syndrome), is now making a difference in common kidney cancers. This adds a new drug type in the kidney cancer space and highlights the value of rare disease research.”
Source: Kimryn Rathmell/X